Once-daily osmotic controlled-release (OROS) methylphenidate (Concerta) in the treatment of 407 children, aged 6-13 years, with ADHD who were known MPH responders, was evaluated in a 24-month multicenter, open-label, nonrandomized study, and reported from the Massachusetts General Hospital, Boston. In 289 (71%) who completed 12 months’treatment, OROS MPH was well tolerated and effectiveness was maintained up to 12 months. Of 118 who failed to complete the trial period, 31 (7.6%) discontinued for lack of effectiveness, and 28 (6.9%) for adverse events, including tics (7), and insomnia (5). New onset of tics occurred in 23 (6.4%) subjects. [1]